California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, allocating roughly half the proceeds to a single University of California-affiliated nonprofit institute selected under narrow eligibility criteria and the remainder through competitive grants focused on cancer, heart disease, and Alzheimer’s. The measure requires price discounts on resulting treatments and mandates repayment from the state General Fund, estimated at about $500 million annually for 25 years. Recent reporting has highlighted the initiative’s structure, which analysts note effectively directs the largest share to one specific research entity whose prominent backer helped shape the proposal. These design and fiscal concerns appear to underpin the current trader consensus leaning against passage ahead of the November 2026 vote.